Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT01130142 is registered in ClinicalTrials.gov with Infinity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01130142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01130142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
Lead sponsor
Infinity Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2010
Completion date
May 31, 2012
Enrollment
122 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer